Conference
Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress
Abstract
Abstract
Background: Genotyping tumor tissue in time for clinical treatment decision-making has been challenging in advanced non-small cell lung cancer (NSCLC). Next-generation sequencing (NGS) of cell-free DNA (cfDNA) obtained from blood samples may improve diagnostic testing, with faster turnaround time (TAT) and potential cost savings. This study defines the added value of cfDNA versus tumor tissue genotyping in patients …
Authors
Agulnik J; Law JH; Juergens R; Laskin J; Laurie S; Hao D; Ezeife DA; Le LW; Kiedrowski LA; Lanman RB
Volume
26
Pagination
pp. a26-a26
Publisher
American Association for Cancer Research (AACR)
Publication Date
June 1, 2020
DOI
10.1158/1557-3265.liqbiop20-a26
Conference proceedings
Clinical Cancer Research
Issue
11_Supplement
ISSN
1078-0432